Document is current
Any future updates will be listed below
-
Authors
Le, Xiuning https://orcid.org/0000-0002-8554-1185
Robichaux, Jacqulyne P. https://orcid.org/0000-0001-8812-7054
Nilsson, Monique
Vijayan, R. S. K.
Ravichandran, Ashwin
Wu, Jia https://orcid.org/0000-0001-8392-8338
Elamin, Yasir Y. https://orcid.org/0000-0002-5312-909X
Hong, Lingzhi https://orcid.org/0000-0001-6553-3279
Pei, Jun
He, Jun
Patel, Sonia
Udagawa, Hibiki
Mani, Sriramvignesh
Jang, Chang Woon
Clarke, Jeffrey M.
Tchekmedyian, Nishan
Goldman, Jonathan W. https://orcid.org/0000-0002-4925-8243
Socinski, Mark
Bhat, Gajanan
Leu, Sharon
Bunn, Veronica
Su, Zhenqiang
Vincent, Sylvie https://orcid.org/0000-0002-7247-2467
Lawson, John W.
Cross, Jason B.
Heymach, John V. https://orcid.org/0000-0001-9068-8942
- License Information
-
More Information
Article History
Received: 26 April 2023
Accepted: 1 July 2025
First Online: 24 September 2025
Competing interests
: Xiuning Le, Consulting/advisory fees from Eli Lilly, EMD Serono (Merck KGaA), AstraZeneca, Spectrum Pharmaceutics, Novartis, Regeneron, Boehringer Ingelheim, Hengrui Therapeutics, Bayer, Teligene, Taiho, Daiichi Sankyo, Janssen, Blueprint Medicines, Sensei Biotherapeutics, SystImmune, ArriVent, Abion, BlossomHill, and AbbVie. Research Funding to Institution from Eli Lilly, EMD Serono, ArriVent, Dizal, Teligene, Regeneron, Janssen, ThermoFisher, Takeda, and Boehringer Ingelheim. Travel Support from EMD Serono, Janssen, and Spectrum Pharmaceutics. Jacqulyne P. Robichaux, Employment and stock/shares with AstraZeneca; inventor on patents held by UT MD Anderson Cancer Center licensed to Spectrum Pharmaceuticals for treatment of EGFR/HER2 exon 20 mutant cancers and inventor on patent held by UT MD Anderson Cancer Center regarding EGFR mutation subtypes and methods of treatment. Monique Nilsson, Patent and license fees from Spectrum. R.S.K.Vijayan, No competing interest. Ashwin Ravichandran, No competing interest. Rizwan Qureshi, No competing interest. Jia Wu, Siemens Healthcare. Yasir Y. Elamin, reports honoraria: CME Matters, Clinical Care Options CME, Research to Practice CME, Medscape CME, Biomedical Learning Institute CME, MLI Peerview CME, Prime Oncology CME, Projects in Knowledge CME, Rockpointe CME, MJH Life Sciences CME, Medical Educator Consortium, HMP education consulting or advisory role: AstraZeneca, Genentech (Roche), Exelixis, Takeda Pharmaceuticals, Eli Lilly, Amgen, Iovance Biotherapeutics, Blueprint Pharmaceuticals, Regeneron Pharmaceuticals, Natera, Sanofi, D2G Oncology, Surface Oncology, Turning Point Therapeutics, Mirati Therapeutics, Gilead Sciences, Abbive, Summit Therapeutics, Novartis, Novocure, Janssen Oncology, Anheart Therapeutics Reserach Funding: Genentech/Roche, Merck, Novartis, Boehringer Ingelheim, Exelixis, Nektart Therapeutics, Takeda Pharmaceuticals, Adaptimmune, GlaxoSmithKline, Janssen Pharmaceuticals, Abbvie Pharmaceuticals and Novocure. M.V.N. reports research funding to institution: Mirati, Novartis, Checkmate (ended), Alaunos, AstraZeneca, Pfizer, Genentech, Navire; consultant or advisory board: Mirati, Merck/MSD, Novartis and Genentech. Lingzhi Hong, No competing interest. Jun Pei, No competing interest. Jun He, No competing interest. Sonia Patel. Employment from BioNTech. Hibiki Udagawa, research grants from Takeda and Boehringer Ingelheim outside the current study. Sriramvignesh Mani, No competing interest. Chang Woon Jang, No competing interest. Jeffrey M. Clarke, Bristol-Myers Squibb, Genentech, Spectrum, Adaptimmune, AbbVie, Moderna, AstraZeneca, Grid Therapeutics, Abel Zeta, Amgen, Pfizer. Speaking: Merck, AstraZeneca, Amgen. Travel: AstraZeneca, BMS, Amgen. Advisory: AstraZeneca, Merck, Pfizer, Spectrum, Genentech, Novartis, Turning Point, G1 Therapeutics, Vivacitas, Omega, Amgen, Corbus, Sanofi, Coherus, CDR Life, AbbVie, Blackdiamond. Nishan Tchekmedyian, Stock and Other Ownership Interests: Portola Pharmaceuticals, Halozyme (I), Infinity Pharmaceuticals (I), Global therapeutics (I), Biomarin (I), Exelixis (I), Trillium Therapeutics (I)Consulting or Advisory Role: Seattle Genetics, IntrinsiQ, Foundation Medicine, Amgen. Research Funding: Bristol Myers Squibb (Inst), Spectrum Pharmaceuticals (Inst), Turning Point Therapeutics (Inst), Cullinan Oncology (Inst), Rain Therapeutics (Inst), Takeda (Inst), Amgen (Inst). Travel, Accommodations, Expenses: IntrinsiQ. Jonathan W. Goldman, Consulting or Advisory Role: AstraZeneca, Bristol Myers Squibb, Lilly, Amgen, Pfizer. Research Funding: Lilly (Inst), Genentech/Roche (Inst), Bristol-Myers Squibb (Inst), AstraZeneca/MedImmune (Inst), Array BioPharma (Inst), AbbVie, Corvus Pharmaceuticals (Inst), Spectrum Pharmaceuticals (Inst), Advaxis (Inst), Pfizer (Inst). Travel, Accommodations, Expenses: AstraZeneca. Mark Socinski, Honoraria: Genentech, Bristol Myers Squibb, Celgene, AstraZeneca, Guardant Health, Bayer, Merck, Roche/Genentech, Lilly, Genentech, AstraZeneca, MedImmune, Lilly, Janssen, Novartis. Speakers’ Bureau: Genentech, Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Bayer, Merck, Amgen, Blueprint Medicines, G1 Therapeutics, Guardant Health, Lilly, Regeneron/Sanofi, Jazz Pharmaceuticals, Janssen Oncology. Research Funding: Genentech (Inst), Spectrum Pharmaceuticals (Inst), AstraZeneca/MedImmune (Inst). Gajanan Bhat, Employment from Spectrum Therapeutics. Sharon Leu, Employment from Spectrum Therapeutics. Veronica Bunn, Employment from Takeda. Zhenqiang Su, Employment from Takeda. Sylvie Vincent, Employment from Takeda. John W. Lawson, No competing interest. Jason B. Cross, No competing interests. John V. Heymach, Advisory Committees: Genentech, Mirati Therapeutics, Eli Lilly, Janssen, Boehringer Ingelheim, Regeneron, Takeda, BerGenBio, Jazz, Curio Science, Novartis, AstraZeneca, BioAlta, Sanofi, Spectrum, GlaxoSmithKline, EMD Serono, BluePrint Medicine and Chugai; research support: AstraZeneca, Boehringer Ingelheim, Spectrum, Mirati, Bristol Myers Squibb and Takeda; licensing or royalties: Spectrum.
